A tumorágy kiegészíto{double acute} besugárzásának hatása a lokális daganatmentességre emlo{double acute}megtartó mu{double acute}tét után: Az Országos Onkológiai Intézet randomizált "boost" vizsgálatának elso{double acute} eredményei

C. Polgár, J. Fodor, Orosz Zsolt, T. Major, Mangel László, Nagy Z. Takácsi, Z. Sulyok, A. Somogyi, Tóth József, I. Köves, M. Kásler, Németh György

Research output: Article

1 Citation (Scopus)

Abstract

Purpose: To evaluate the effect of tumour bed boost on local tumour control (LTC) after breast conserving surgery in a prospective study. Methods: Between 1995 and 1998, 207 women with early invasive breast cancer who underwent conservative operation were treated by 50 Gy irradiation to the whole breast and then randomly assigned to receive either no further radiotherapy (n=103) or a boost to the tumour bed (n=104) with either 16 Gy electron (n=52) or 12-14.25 Gy high dose rate brachytherapy (n=52). Results: At a median follow-up of 4.25 years the crude rate of local recurrence was 6.7% with and 13.6% without boost. The respective rates of tumour bed relapse were 3.8% vs. 10.7%. The 4 year probability of LTC, relapse-free survival and breast cancer-specific survival was 94.2% vs. 85.1% (p=0.1176), 82.3% vs. 67.2% (p=0.0438) and 84.8% vs. 90.9% (p=0.1111), respectively, in favour of the boost group. Systemic treatments had no significant impact on LTC (88.9% with and 89.6% without systemic treatment, p=0.8858). Conclusion: Tumour bed boost decreased the incidence of local and tumor bed relapses with a reduction of 50% and 64%, respectively. Relapse-free survival was improved significantly with boost. However, the influence of boost treatment on breast cancer-specific survival should be tested in further studies. In spite of the higher incidence of late radiation side effects in the boost arm, boost dose is strongly recommended for patients at high risk for local recurrence. The final results of the EORTC trial and other ongoing studies will help to clarify the indication of boost dose according to prognostic subgroups.

Original languageHungarian
Pages (from-to)385-391
Number of pages7
JournalMagyar Onkologia
Volume45
Issue number5
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Oncology

Cite this

@article{7425d237f33d477f8b9775bb4313d397,
title = "A tumor{\'a}gy kieg{\'e}sz{\'i}to{double acute} besug{\'a}rz{\'a}s{\'a}nak hat{\'a}sa a lok{\'a}lis daganatmentess{\'e}gre emlo{double acute}megtart{\'o} mu{double acute}t{\'e}t ut{\'a}n: Az Orsz{\'a}gos Onkol{\'o}giai Int{\'e}zet randomiz{\'a}lt {"}boost{"} vizsg{\'a}lat{\'a}nak elso{double acute} eredm{\'e}nyei",
abstract = "Purpose: To evaluate the effect of tumour bed boost on local tumour control (LTC) after breast conserving surgery in a prospective study. Methods: Between 1995 and 1998, 207 women with early invasive breast cancer who underwent conservative operation were treated by 50 Gy irradiation to the whole breast and then randomly assigned to receive either no further radiotherapy (n=103) or a boost to the tumour bed (n=104) with either 16 Gy electron (n=52) or 12-14.25 Gy high dose rate brachytherapy (n=52). Results: At a median follow-up of 4.25 years the crude rate of local recurrence was 6.7{\%} with and 13.6{\%} without boost. The respective rates of tumour bed relapse were 3.8{\%} vs. 10.7{\%}. The 4 year probability of LTC, relapse-free survival and breast cancer-specific survival was 94.2{\%} vs. 85.1{\%} (p=0.1176), 82.3{\%} vs. 67.2{\%} (p=0.0438) and 84.8{\%} vs. 90.9{\%} (p=0.1111), respectively, in favour of the boost group. Systemic treatments had no significant impact on LTC (88.9{\%} with and 89.6{\%} without systemic treatment, p=0.8858). Conclusion: Tumour bed boost decreased the incidence of local and tumor bed relapses with a reduction of 50{\%} and 64{\%}, respectively. Relapse-free survival was improved significantly with boost. However, the influence of boost treatment on breast cancer-specific survival should be tested in further studies. In spite of the higher incidence of late radiation side effects in the boost arm, boost dose is strongly recommended for patients at high risk for local recurrence. The final results of the EORTC trial and other ongoing studies will help to clarify the indication of boost dose according to prognostic subgroups.",
author = "C. Polg{\'a}r and J. Fodor and Orosz Zsolt and T. Major and Mangel L{\'a}szl{\'o} and Tak{\'a}csi, {Nagy Z.} and Z. Sulyok and A. Somogyi and T{\'o}th J{\'o}zsef and I. K{\"o}ves and M. K{\'a}sler and N{\'e}meth Gy{\"o}rgy",
year = "2001",
language = "Hungarian",
volume = "45",
pages = "385--391",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "5",

}

TY - JOUR

T1 - A tumorágy kiegészíto{double acute} besugárzásának hatása a lokális daganatmentességre emlo{double acute}megtartó mu{double acute}tét után

T2 - Az Országos Onkológiai Intézet randomizált "boost" vizsgálatának elso{double acute} eredményei

AU - Polgár, C.

AU - Fodor, J.

AU - Zsolt, Orosz

AU - Major, T.

AU - László, Mangel

AU - Takácsi, Nagy Z.

AU - Sulyok, Z.

AU - Somogyi, A.

AU - József, Tóth

AU - Köves, I.

AU - Kásler, M.

AU - György, Németh

PY - 2001

Y1 - 2001

N2 - Purpose: To evaluate the effect of tumour bed boost on local tumour control (LTC) after breast conserving surgery in a prospective study. Methods: Between 1995 and 1998, 207 women with early invasive breast cancer who underwent conservative operation were treated by 50 Gy irradiation to the whole breast and then randomly assigned to receive either no further radiotherapy (n=103) or a boost to the tumour bed (n=104) with either 16 Gy electron (n=52) or 12-14.25 Gy high dose rate brachytherapy (n=52). Results: At a median follow-up of 4.25 years the crude rate of local recurrence was 6.7% with and 13.6% without boost. The respective rates of tumour bed relapse were 3.8% vs. 10.7%. The 4 year probability of LTC, relapse-free survival and breast cancer-specific survival was 94.2% vs. 85.1% (p=0.1176), 82.3% vs. 67.2% (p=0.0438) and 84.8% vs. 90.9% (p=0.1111), respectively, in favour of the boost group. Systemic treatments had no significant impact on LTC (88.9% with and 89.6% without systemic treatment, p=0.8858). Conclusion: Tumour bed boost decreased the incidence of local and tumor bed relapses with a reduction of 50% and 64%, respectively. Relapse-free survival was improved significantly with boost. However, the influence of boost treatment on breast cancer-specific survival should be tested in further studies. In spite of the higher incidence of late radiation side effects in the boost arm, boost dose is strongly recommended for patients at high risk for local recurrence. The final results of the EORTC trial and other ongoing studies will help to clarify the indication of boost dose according to prognostic subgroups.

AB - Purpose: To evaluate the effect of tumour bed boost on local tumour control (LTC) after breast conserving surgery in a prospective study. Methods: Between 1995 and 1998, 207 women with early invasive breast cancer who underwent conservative operation were treated by 50 Gy irradiation to the whole breast and then randomly assigned to receive either no further radiotherapy (n=103) or a boost to the tumour bed (n=104) with either 16 Gy electron (n=52) or 12-14.25 Gy high dose rate brachytherapy (n=52). Results: At a median follow-up of 4.25 years the crude rate of local recurrence was 6.7% with and 13.6% without boost. The respective rates of tumour bed relapse were 3.8% vs. 10.7%. The 4 year probability of LTC, relapse-free survival and breast cancer-specific survival was 94.2% vs. 85.1% (p=0.1176), 82.3% vs. 67.2% (p=0.0438) and 84.8% vs. 90.9% (p=0.1111), respectively, in favour of the boost group. Systemic treatments had no significant impact on LTC (88.9% with and 89.6% without systemic treatment, p=0.8858). Conclusion: Tumour bed boost decreased the incidence of local and tumor bed relapses with a reduction of 50% and 64%, respectively. Relapse-free survival was improved significantly with boost. However, the influence of boost treatment on breast cancer-specific survival should be tested in further studies. In spite of the higher incidence of late radiation side effects in the boost arm, boost dose is strongly recommended for patients at high risk for local recurrence. The final results of the EORTC trial and other ongoing studies will help to clarify the indication of boost dose according to prognostic subgroups.

UR - http://www.scopus.com/inward/record.url?scp=84875018331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875018331&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84875018331

VL - 45

SP - 385

EP - 391

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 5

ER -